Antiresorptive Drug–Related Osteonecrosis of the Jaw - 21/03/14

Doi : 10.1016/j.cden.2013.12.006

Jettie Uyanne, DDS ^a,^b,^⁎ , Colonya C. Calhoun, DDS, PhD ^c,^d, Anh D. Le, DDS, PhD ^a,^e
^a Division of Oral and Maxillofacial Surgery, Herman Ostrow School of Dentistry of USC, 925 West 34th Street, Los Angeles, CA 90089-0641, USA
^b Division of Oral and Maxillofacial Surgery, Harbor UCLA, 1000 West Carson Street, Torrance, CA 90509, USA
^c Division of Oral and Maxillofacial Surgery, Harbor UCLA, 1000 West Carson Street, Mailbox #19, Torrance, CA 90509, USA
^d Charles R. Drew University, Los Angeles, CA, USA
^e Department of Oral and Maxillofacial Surgery and Pharmacology, University of Pennsylvania School of Dental Medicine, Penn Medicine Hospital of the University of Pennsylvania, 240 South 40th Street, Philadelphia, PA 19104-6030, USA

^∗Corresponding author. Division of Oral and Maxillofacial Surgery, Herman Ostrow School of Dentistry of USC, Norris Dental Science Center, 925 West 34th Street, DEN 146, Los Angeles, CA 90089-0641.

Résumé

Nitrogen-containing and non–nitrogen-containing bisphosphonates have been implicated in the development of osteonecrosis of the jaw (ONJ), a condition termed bisphosphonate-related OHJ. Other antiresorptive drugs have been implicated in the development of OHJ, hence the new term antiresorptive drug–related ONJ. The underlying pathogenesis remains unclear, and no definite diagnosis or cure has been established for this debilitating condition. This article reviews some of the most common antiresorptive drugs with their associated risks of ONJ and the current understanding of the pathogenesis ONJ, and summarizes current clinical guidelines.

Le texte complet de cet article est disponible en PDF.

Keywords : Bisphosphonate, Denosumab, Osteonecrosis of the jaw, Zoledronate